Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014 Anthera Pharmaceuticals, Inc. , announced financial results and operational revise for the third quarter ended September 30 today, 2014 durable erection click here . September 30 Net loss for the three months ended, 2014 was $7.0 million, in comparison to $5.8 million for the same period in 2013. The increase in net loss is mainly driven by higher research and development expense because of continued enrollment improvement in both our Stage 3 systemic lupus erythematosus clinical research, CHABLIS-SC1, and Phase 2/3 IgA nephropathy clinical study, BRIGHT-SC. Net reduction for the nine a few months ended September 30, 2014 was $22.2 million, compared with net lack of $21.7 million for the same period in 2013.
In addition to Enhance, the firms are conducting three extra studies involving more than 20,000 high-risk patients. Regardless of the data, Goldman Sachs analyst James Kelly reaffirmed a Buy ranking on Schering-Plough, contacting the results a non-event which doesn’t represent Vytorin’s commercial leads. He said the results reaffirmed the drug’s safety, which had been the key concern of Wall Road. In January Earlier, Merck Chief Executive Richard T. Clark was likewise assured in reaffirming his expectation that Vytorin would maintain steadily its position in the cholesterol drug market.